Breast Cancer

An effective alternative to mastectomy for early stage disease regardless of age or hormone receptor status.

A pair of studies could change the way patients are evaluated for mutations of BRCA1 and BRCA2, two cancer susceptibility genes closely associated with breast and ovarian cancers, as well as other tumor types.

Does "think pink" actually raise awareness of breast cancer?

Carrie Stricker from the Abramson Cancer Center of the University of Pennsylvania on the Efficacy of Survivorship Care Plans for Posttreatment Breast Cancer Survivors.

Forty years after the declaration of war on cancer, one of the most profound shifts in cancer care today is a new focus on treating those living beyond cancer, as well as those living with cancer.

Whether surgically or medically induced, early menopause forces women to deal with a host of emotional, physical, and practical issues.

Detecting hereditary cancer and providing genetic counseling can help prevent a new primary cancer and may also help to protect family members from developing cancer.

Understanding the genetic basis of breast and ovarian cancers is essential to providing patients with effective preventive and/or management strategies that can improve outcomes.

Dr. Linda Vahdat, from New York-Presbyterian Hospital, Discusses the Side Effects of Halaven

Beth Baughman DuPree, MD, FACS, discussed the latest in breast cancer care at the 3rd Annual NCONN Conference.

Dr. Linda Vahdat, from the New York-Presbyterian Hospital, Compares Halaven and Ixempra Neuropathy

Promising study results were released at the San Antonio Breast Cancer Symposium.

Dr. Beth DuPree from Holy Redeemer Health System Provides Z11 Trial Takeaway Points

Dr. Wayne Bardwell from UCSD Cancer Center on Cancer-Related Variables and Depression

Now more than ever, oncology nurses need to be able to fill the knowledge gap and accurately educate their patients and the public about cancer screening tests and their frequency.

Personal perspectives from oncology nurses of abstracts presented at ASCO on research with the potential to change practice, important studies that failed to meet expectations, and topics particularly relevant to oncology nurses.

In postmenopausal diabetic women, metformin use was associated with lower ER and PR breast cancer incidence.

Patients with breast cancer who undertook yoga following radiotherapy derived physical and emotional benefi ts from the ancient Indian practice, according to research presented at ASCO.

Breast cancer survivors who stop working during chemotherapy may face the loss of long-term employment for several years after their diagnosis.

A randomized trial comparing survivorship care plans with standard oncologist discharge visits in patients with breast cancer found no differences in outcomes among the groups.

Recent study findings raise questions about how well computers interpret mammograms.

3D mammogram system approved, NCCN 2011 Avastin breast cancer guidelines, and the approval of generic docetaxel.

ASCO releases new recommendations amid growing therapeutic options and fresh concerns about serious skeletal-related events.

Contrary to the traditionally slow pace of research adoption, the American College of Surgeons Oncology Group's Z0011 trial has seemingly changed practice overnight

A breast cancer diagnosis is a highly distressing, life-changing experience

Two studies presented at SABCS refined knowledge about how to prevent lymphedema in patients with breast cancer.

The FDA is examining a potential link between breast implants and anaplastic large cell lymphoma (ALCL), a rare and aggressive form of non-Hodgkin lymphoma.

Monica Knoll is no stranger to cancer. Her sister is a breast cancer survivor and her father died from esophageal cancer. Still, she was not prepared for a breast cancer diagnosis in 2000

Being obese at the time operable breast cancer is diagnosed is associated with inferior outcomes in women with estrogen receptor (ER) or progesterone receptor (PR)positive, HER2-negative breast cancer.

Hospitals, pharmacists, and physicians across the United States are reporting shortages of critical anticancer drugs, including carboplatin, cisplatin, dacarbazine, fludarabine, and cytarabine.